SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

@article{Hazel2016SIRFLOXRP,
  title={SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.},
  author={G. van Hazel and V. Heinemann and N. Sharma and M. Findlay and J. Ricke and M. Peeters and D. Perez and B. Robinson and A. Strickland and T. Ferguson and Javier Rodr{\'i}guez and H. Kroening and I. Wolf and V. Ganju and E. Walpole and E. Boucher and T. Tichler and E. Shacham-Shmueli and A. Powell and P. Eliadis and R. Isaacs and D. Price and F. Moeslein and J. Taieb and Geoff Bower and V. Gebski and Mark van Buskirk and D. Cade and K. Thurston and P. Gibbs},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 15},
  pages={
          1723-31
        }
}
  • G. van Hazel, V. Heinemann, +27 authors P. Gibbs
  • Published 2016
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untreated metastatic colorectal cancer. [...] Key MethodPATIENTS AND METHODS Chemotherapy-naïve patients with liver metastases plus or minus limited extrahepatic metastases were randomly assigned to receive either…Expand
209 Citations

Paper Mentions

Interventional Clinical Trial
The main objective of the SIRTCI study is to evaluate the safety and efficacy of the combination chemotherapy (XELOX: Capecitabine plus oxaliplatin), anti-angiogenic (Bevacizumab… Expand
ConditionsImmune Checkpoint Inhibitor, Internal Radiotherapy, Metastatic Colorectal Cancer, (+2 more)
InterventionDevice, Drug
Interventional Clinical Trial
This study is a randomized, multi-center study that will compare the efficacy and safety of selective internal radiation therapy (SIRT) using SIR-Spheres microspheres plus a standard… Expand
ConditionsColorectal Cancer Metastatic
InterventionDevice, Drug
Interventional Clinical Trial
This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard… Expand
ConditionsColorectal Cancer, Colorectal Carcinoma, Liver Metastases
InterventionDevice, Drug
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
  • L. Saltz, S. Clarke, +10 authors J. Cassidy
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
  • 2,551
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
  • H. Hochster, L. Hart, +9 authors E. Hedrick
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
  • 521
  • PDF
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
  • 131
Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.
  • 478
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
  • 296
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
  • 2,712
  • PDF
...
1
2
3
4
5
...